Mediastinitis and Staphylococcus Aureus
MEDIASTAPH
Immunological and Bacteriological Approaches to the Development of Postoperative Mediastinitis With Staphylococcus Aureus
1 other identifier
observational
27
1 country
1
Brief Summary
Cardiac surgery with extracorporeal circulation (ECC) yields a deep immune system dysfunction that exposes patients to postoperative infectious complications. Among these, post-operative mediastinitis with Staphylococcus aureus (SA) generates significant morbidity and mortality. Two radically different approaches have been proposed in recent years to reduce the incidence of this complication. A first approach has attempted, without real success, to decrease postoperative immunosuppression. The second, more efficient, consisted of screening and preoperatively treating patients colonized with SA. However, although its incidence has decreased, postoperative mediastinitis remains a terrible nosocomial infection. The authors believe that a thorough analysis of the immunological changes induced by cardiac surgery will initiate active therapeutics to reduce the post-operative immunosuppression phase, thereby decreasing the risk of nosocomial infections. In addition, a study of the interactions between the operated (host) and staphylococcus aureus (pathogenic) immune systems will provide a better understanding of the mechanisms that expose patients to this bacterium.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jul 2016
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 4, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2017
CompletedFirst Submitted
Initial submission to the registry
August 22, 2017
CompletedFirst Posted
Study publicly available on registry
August 25, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
September 29, 2019
CompletedDecember 14, 2022
December 1, 2022
12 months
August 22, 2017
December 13, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Variation of plasma IDO activity
IDO activity is evaluated by the Kynurenin / Tryptophan ratio before and after ECC. Enzymatic activities will be measured by high performance liquid chromatography (HPLC) on pre- and post-operative blood tests
Baseline and the morning following surgery
Secondary Outcomes (10)
Variation of phagocytosis capacity of PMNs
Baseline and the morning following surgery
Variation of bactericidal capacity of PMNs
Baseline and the morning following surgery
Variation of phagocytosis capacity of macrophages
Baseline and the morning following surgery
Variation of bactericidal capacity of macrophages
Baseline and the morning following surgery
Effect of an inhibitor of IDO on phagocytosis capacities of PMNs
The day following surgery
- +5 more secondary outcomes
Study Arms (1)
Patients with ECC
No intervention
Interventions
Patients will undergo standard clinical routine practice in this indication
Eligibility Criteria
Patients in the aftermath of an ECC for cardiac surgery are investigated to look for the origin of a hypo-reactivity of PMNs and macrophages during exposure to staphylococcus aureus
You may qualify if:
- Patients over 18 years of age
- Patients who require cardiac surgery (valvular and / or coronary) with extracorporeal circulation.
- Chronic respiratory diseases,
- Preoperative left ventricular dysfunction (LVEF \<50%),
- Immunosuppression (HIV infection, systemic corticosteroid therapy, history of cancer in the year before surgery),
- Persons subject to legal protection (safeguard of justice, curatorship, guardianship),
- Persons deprived of liberty.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rennes Hospital University
Rennes, 35033, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Jean-Marc TADIE, Md, PhD
CHU Rennes
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 22, 2017
First Posted
August 25, 2017
Study Start
July 4, 2016
Primary Completion
July 1, 2017
Study Completion
September 29, 2019
Last Updated
December 14, 2022
Record last verified: 2022-12
Data Sharing
- IPD Sharing
- Will not share